The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.

Saved in:
Bibliographic Details
Title: The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.
Authors: Kennedy ME; Department of Neuroscience, Merck Research Laboratories, Kenilworth, NJ 07033, USA. matthew.kennedy@merck.com andy.stamford1@gmail.com ericmcparker@comcast.net mark.forman@merck.com., Stamford AW; Department of Global Chemistry, Merck Research Laboratories, Kenilworth, NJ 07033, USA. matthew.kennedy@merck.com andy.stamford1@gmail.com ericmcparker@comcast.net mark.forman@merck.com., Chen X; Department of Neuroscience, Merck Research Laboratories, Kenilworth, NJ 07033, USA., Cox K; Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, NJ 07033, USA., Cumming JN; Department of Global Chemistry, Merck Research Laboratories, Kenilworth, NJ 07033, USA., Dockendorf MF; Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, NJ 07033, USA., Egan M; Department of Clinical Research, Merck Research Laboratories, Kenilworth, NJ 07033, USA., Ereshefsky L; PAREXEL, Glendale, CA 91206, USA., Hodgson RA; Department of Neuroscience, Merck Research Laboratories, Kenilworth, NJ 07033, USA., Hyde LA; Department of Neuroscience, Merck Research Laboratories, Kenilworth, NJ 07033, USA., Jhee S; PAREXEL, Glendale, CA 91206, USA., Kleijn HJ; Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, NJ 07033, USA., Kuvelkar R; Department of Neuroscience, Merck Research Laboratories, Kenilworth, NJ 07033, USA., Li W; Department of Global Chemistry, Merck Research Laboratories, Kenilworth, NJ 07033, USA., Mattson BA; Department of Safety Assessment, Merck Research Laboratories, West Point, PA 19446, USA., Mei H; Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, NJ 07033, USA., Palcza J; Department of Biostatistics, Merck Research Laboratories, Kenilworth, NJ 07033, USA., Scott JD; Department of Global Chemistry, Merck Research Laboratories, Kenilworth, NJ 07033, USA., Tanen M; Translational Biomarkers Department, Merck Research Laboratories, Kenilworth, NJ 07033, USA., Troyer MD; Department of Translational Medicine, Merck Research Laboratories, Kenilworth, NJ 07033, USA., Tseng JL; Department of Translational Medicine, Merck Research Laboratories, Kenilworth, NJ 07033, USA., Stone JA; Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck Research Laboratories, Kenilworth, NJ 07033, USA., Parker EM; Department of Neuroscience, Merck Research Laboratories, Kenilworth, NJ 07033, USA. matthew.kennedy@merck.com andy.stamford1@gmail.com ericmcparker@comcast.net mark.forman@merck.com., Forman MS; Department of Translational Medicine, Merck Research Laboratories, Kenilworth, NJ 07033, USA. matthew.kennedy@merck.com andy.stamford1@gmail.com ericmcparker@comcast.net mark.forman@merck.com.
Source: Science translational medicine [Sci Transl Med] 2016 Nov 02; Vol. 8 (363), pp. 363ra150.
Publication Type: Journal Article
Journal Info: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1946-6242
DOI:10.1126/scitranslmed.aad9704